JP2024531238A - がんを処置するための方法および組成物 - Google Patents

がんを処置するための方法および組成物 Download PDF

Info

Publication number
JP2024531238A
JP2024531238A JP2024508686A JP2024508686A JP2024531238A JP 2024531238 A JP2024531238 A JP 2024531238A JP 2024508686 A JP2024508686 A JP 2024508686A JP 2024508686 A JP2024508686 A JP 2024508686A JP 2024531238 A JP2024531238 A JP 2024531238A
Authority
JP
Japan
Prior art keywords
days
compound
administering
independently
pure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024508686A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023018891A5 (https=
JP2024531238A5 (https=
Inventor
スティーブン フラクトマン，
マシュー パリス，
Original Assignee
オンコノヴァ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オンコノヴァ セラピューティクス， インコーポレイテッド filed Critical オンコノヴァ セラピューティクス， インコーポレイテッド
Publication of JP2024531238A publication Critical patent/JP2024531238A/ja
Publication of JPWO2023018891A5 publication Critical patent/JPWO2023018891A5/ja
Publication of JP2024531238A5 publication Critical patent/JP2024531238A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024508686A 2021-08-12 2022-08-11 がんを処置するための方法および組成物 Pending JP2024531238A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163232409P 2021-08-12 2021-08-12
US63/232,409 2021-08-12
PCT/US2022/040092 WO2023018891A1 (en) 2021-08-12 2022-08-11 Methods and compositions for treating cancer

Publications (3)

Publication Number Publication Date
JP2024531238A true JP2024531238A (ja) 2024-08-29
JPWO2023018891A5 JPWO2023018891A5 (https=) 2025-08-19
JP2024531238A5 JP2024531238A5 (https=) 2025-08-19

Family

ID=85200519

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024508686A Pending JP2024531238A (ja) 2021-08-12 2022-08-11 がんを処置するための方法および組成物

Country Status (11)

Country Link
US (1) US20240299326A1 (https=)
EP (1) EP4384498A1 (https=)
JP (1) JP2024531238A (https=)
CN (1) CN118076583A (https=)
AU (1) AU2022326485A1 (https=)
CA (1) CA3228644A1 (https=)
CO (1) CO2024002786A2 (https=)
GB (1) GB2628229A (https=)
IL (1) IL310759A (https=)
MX (1) MX2024001935A (https=)
WO (1) WO2023018891A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5156389B2 (ja) * 2005-01-05 2013-03-06 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 薬剤耐性増殖性疾患の治療剤
WO2014089483A1 (en) * 2012-12-07 2014-06-12 Onconova Therapeutics, Inc. Methods and compositions for treatment of cancer
JP2018530590A (ja) * 2015-10-14 2018-10-18 タリックス ファーマシューティカルズ リミテッド 表皮水疱症の処置のための方法及び組成物
CA3076610A1 (en) * 2017-09-22 2019-03-28 University Of Miami Methods and compositions for the treatment of epidermolysis bullosa

Also Published As

Publication number Publication date
WO2023018891A1 (en) 2023-02-16
US20240299326A1 (en) 2024-09-12
GB2628229A (en) 2024-09-18
AU2022326485A1 (en) 2024-02-29
MX2024001935A (es) 2024-03-21
CO2024002786A2 (es) 2024-03-18
GB202402730D0 (en) 2024-04-10
CA3228644A1 (en) 2023-02-16
CN118076583A (zh) 2024-05-24
WO2023018891A8 (en) 2023-09-21
IL310759A (en) 2024-04-01
EP4384498A1 (en) 2024-06-19

Similar Documents

Publication Publication Date Title
TWI831916B (zh) 包含tno155和瑞博西尼之藥物組合
AU2002210993B2 (en) Medicinal compositions for concominant use as anticancer agents
WO2017146236A1 (ja) Ａｘｌ阻害剤と免疫チェックポイント阻害剤とを組み合わせて投与することを特徴とする癌治療のための医薬
WO2020177587A1 (zh) 治疗脂肪性肝病和/或脂肪性肝炎的方法
JP6240658B2 (ja) 抗がん活性を有する６−オキソ−１，６−ジヒドロ−ピリダジン誘導体と他の抗腫瘍化合物との組み合わせ
JP2019048822A (ja) Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における２−カルボキサミドシクロアミノウレア誘導体の使用
JPWO2018043530A1 (ja) 抗腫瘍剤、抗腫瘍効果増強剤及び抗腫瘍用キット
AU2003242646A1 (en) Combinations comprising epothilones and pharmaceutical uses thereof
TW202539662A (zh) 抗腫瘤組合物
CN115484944B (zh) 使用ccr9抑制剂和抗il-23阻断抗体治疗炎症性肠病的组合物和方法
CN113939315A (zh) 治疗黑色素瘤的联用药物组合物
JP2024531238A (ja) がんを処置するための方法および組成物
MD4879C1 (ro) Utilizare a derivatului bisamidic al acidului malonic pentru tratarea bolilor alergice şi altor boli umane şi animaliere
EP3967309B1 (en) Quinoline derivative and antibody toripalimab soft tissue sarcoma combination therapy
US12195468B2 (en) TLR7 agonist for treating colorectal cancer and pharmaceutical combination thereof
US20240366610A1 (en) Methods and compositions for treating cancer
JP2026510002A (ja) Ｅｔｂｒ活性化に関連する癌を処置するための方法
JP2024540529A (ja) がんを処置するための方法および組成物
CA3238551A1 (en) Methods and compositions for treating cancer
US20230092001A1 (en) Furaneol glycoside compound, pharmaceutical composition thereof, preparation method therefor, and application thereof
PT1757283E (pt) Potenciador do efeito antitumoral, agente antitumoral e método para a terapia do cancro
CA3138682A1 (en) Tie-2 activators targeting the schlemm's canal
US20240382520A1 (en) Composition for preventing and treating cancer through mitochondrial metabolism regulation containing nanographene structure
JP2024527504A (ja) がんを処置するための方法および組成物
WO2025247187A1 (zh) 抗trop2抗体药物偶联物和抗pd-l1/cd47双特异抗体联合治疗肿瘤的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250808

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250808